3E605854-CC65-4951-8EDB-235FD21FD71F
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.1314060446780552
- age_years
- 33
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.679
- INTERFERON_ALPHA_RESPONSE+0.599
- TGF_BETA_SIGNALING+0.587
- INTERFERON_GAMMA_RESPONSE+0.585
- IL6_JAK_STAT3_SIGNALING+0.488
- NOTCH_SIGNALING+0.467
- APOPTOSIS+0.463
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.457
- INFLAMMATORY_RESPONSE+0.456
- P53_PATHWAY+0.429
Top 10 suppressed
- SPERMATOGENESIS-0.237
- KRAS_SIGNALING_DN-0.194
- E2F_TARGETS-0.133
- G2M_CHECKPOINT-0.079
- PANCREAS_BETA_CELLS-0.058
- BILE_ACID_METABOLISM+0.058
- MYOGENESIS+0.090
- APICAL_SURFACE+0.138
- PEROXISOME+0.168
- FATTY_ACID_METABOLISM+0.171
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | CCA161B9-1E9A-4F8C-8144-B32B5CF76ECC | — | — | 0.934 |
| 2 | BS_2YCJV2VV | low-grade glioma | — | 0.933 |
| 3 | DACCA07A-8F2C-40C5-B8AD-73805E408D85 | — | — | 0.930 |
| 4 | R250 | — | — | 0.925 |
| 5 | A7C71CEF-A5C7-4BAC-9090-9808B029190B | — | — | 0.921 |
| 6 | 44B1F003-553A-4C8A-A6AE-44C49262081C | — | — | 0.917 |
| 7 | 9A593453-3B4C-4557-84BF-E9E902AA0F3F | — | — | 0.917 |
| 8 | 443B59BB-0BFD-459A-896E-FA07AA6C3A45 | — | — | 0.912 |
| 9 | TCGA-FD-A5BU-01A-31R-A26T-07 | — | — | 0.909 |
| 10 | TCGA-ZF-AA56-01A-31R-A39I-07 | — | — | 0.908 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.679 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.599 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.587 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.585 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.488 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.467 | Inavolisib | — uncovered |
| APOPTOSIS | 0.463 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.457 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.456 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.429 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.415 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.409 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.400 | Idelalisib | — uncovered |
| HYPOXIA | 0.394 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.363 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.363 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.345 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.332 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.325 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.320 | Inavolisib | — uncovered |